Growth Metrics

GeneDx Holdings (WGS) Total Current Liabilities (2020 - 2026)

GeneDx Holdings has reported Total Current Liabilities over the past 7 years, most recently at $87.6 million for Q1 2026.

  • Quarterly Total Current Liabilities rose 26.02% to $87.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $87.6 million through Mar 2026, up 26.02% year-over-year, with the annual reading at $108.9 million for FY2025, 98.68% up from the prior year.
  • Total Current Liabilities was $87.6 million for Q1 2026 at GeneDx Holdings, down from $108.9 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $204.6 million in Q2 2022 and troughed at $50.7 million in Q1 2024.
  • The 5-year median for Total Current Liabilities is $84.4 million (2023), against an average of $95.2 million.
  • Year-over-year, Total Current Liabilities skyrocketed 181.77% in 2022 and then tumbled 59.24% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $144.3 million in 2022, then tumbled by 59.24% to $58.8 million in 2023, then fell by 6.8% to $54.8 million in 2024, then surged by 98.68% to $108.9 million in 2025, then fell by 19.53% to $87.6 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's Total Current Liabilities are $87.6 million (Q1 2026), $108.9 million (Q4 2025), and $87.6 million (Q3 2025).